Raw outcome data were checked for quality. Data were labelled as missing values if noise > 100 μV and standard deviation > 20 μV. The effect of iTBS (expressed as MEP size) was tested for normal distribution. Because this was not normally distributed, the median MEP size was used and not the mean MEP size. The median MEP size of baseline was set at 100%. The median MEP outcomes at 0, 10, 20 and 30 minutes after iTBS were expressed as a percentage compared to baseline. Because MEP sizes were not normally distributed, the non-parametric Friedman test (non-parametric test for repeated measures) was conducted to assess whether iTBS induced a significant effect over time, for healthy subjects and Nf1 patients separately. When a significant overall effect was obtained, pairwise comparisons between baseline and time points after iTBS were performed with Wilcoxon tests (post hoc test for repeated measures Friedman test). This research does not include a comparison between the healthy subjects and NF1 patients because the difference in sample size is too